PMID- 29263719
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1724-8914 (Print)
IS  - 1971-3266 (Electronic)
IS  - 1724-8914 (Linking)
VI  - 14
IP  - 2
DP  - 2017 May-Aug
TI  - The LARO-MEN1 study: a longitudinal clinical experience with octreotide 
      Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 
      Syndrome.
PG  - 123-130
LID - 10.11138/ccmbm/2017.14.1.123 [doi]
AB  - Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumoral syndrome, 
      featured by a combination of neoplasms of various endocrine and nonendocrine 
      tissues. Approximately 33% of MEN1-related deaths are due to the malignant 
      behaviour of well-differentiated neuroendocrine tumors (NETs), for which a 
      preventive surgical treatment is not feasible. Somatostatin analogues (SSA) have 
      been employed in the treatment of NETs in the stage of advanced or metastatic 
      disease, in order to control the growth and secretion of tumor lesions. A 
      longitudinal, open label study named "LARO-MEN1" was undertaken in order to 
      assess whether early medical treatment with long-acting SSA could act as a 
      preventive approach in small MEN1-related gastroenteropancreatic (GEP) NETs. 
      Thirty consecutive patients affected by MEN1 were screened and 8 patients with 
      small (<2 cm) NETs and abnormal laboratory values of at least one of the GEP 
      hormones were administered octreotide acetate slow-release formulation (LAR) (10 
      mg i.m. every 28 days). Octreotide LAR was effective in decreasing GEP hormones 
      and overall safe in the majority of patients up to six years of treatment, 
      maintaining the disease stable also in terms of tumor size. The positive outcomes 
      of this study in MEN1 patients reinforce the results obtained in advanced NETs on 
      the use of SSA, opening to the opportunity for preventive use of octreotide LAR, 
      aimed to delay or even avoid surgery in these patients.
FAU - Cioppi, Federica
AU  - Cioppi F
AD  - Bone and Mineral Metabolism Unit, Department of Surgery and Translational 
      Medicine, University of Florence, Florence, Italy.
FAU - Cianferotti, Luisella
AU  - Cianferotti L
AD  - Bone and Mineral Metabolism Unit, Department of Surgery and Translational 
      Medicine, University of Florence, Florence, Italy.
FAU - Masi, Laura
AU  - Masi L
AD  - Bone and Mineral Metabolism Unit, Department of Surgery and Translational 
      Medicine, University of Florence, Florence, Italy.
FAU - Giusti, Francesca
AU  - Giusti F
AD  - Bone and Mineral Metabolism Unit, Department of Surgery and Translational 
      Medicine, University of Florence, Florence, Italy.
FAU - Brandi, Maria Luisa
AU  - Brandi ML
AD  - Bone and Mineral Metabolism Unit, Department of Surgery and Translational 
      Medicine, University of Florence, Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20171025
PL  - Italy
TA  - Clin Cases Miner Bone Metab
JT  - Clinical cases in mineral and bone metabolism : the official journal of the 
      Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases
JID - 101250935
PMC - PMC5726195
OTO - NOTNLM
OT  - MEN1
OT  - neuroendocrine tumors
OT  - somatostatin analogs
OT  - somatostatin receptors
COIS- Conflict of interest C.F., C.L., M.L., and G.F. declare that have no conflict of 
      interest to disclose in general and regarding this paper. B.M.L. declares that 
      has received grants and consulting fees from Alexion, Abiogen Pharma, Amgen, 
      Bruno Farmaceutici, Eli Lilly, MSD, NPS, Shire, SPA, Servier.
EDAT- 2017/12/22 06:00
MHDA- 2017/12/22 06:01
PMCR- 2017/05/01
CRDT- 2017/12/22 06:00
PHST- 2017/12/22 06:00 [entrez]
PHST- 2017/12/22 06:00 [pubmed]
PHST- 2017/12/22 06:01 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - 123-130 [pii]
AID - 10.11138/ccmbm/2017.14.1.123 [doi]
PST - ppublish
SO  - Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):123-130. doi: 
      10.11138/ccmbm/2017.14.1.123. Epub 2017 Oct 25.